Citation Impact
Citing Papers
Reporters of TCR signaling identify arthritogenic T cells in murine and human autoimmune arthritis
2019
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
2016
Effective treatment of severe COVID-19 patients with tocilizumab
2020 Standout
Anti-interleukin-6 therapy in rheumatoid arthritis.
2010
Clinical safety of tocilizumab in rheumatoid arthritis
2010
Synovitis in osteoarthritis: current understanding with therapeutic implications
2017 Standout
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
2013
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
2010
Targeting Interleukin-6 Signaling in Clinic
2019
Rheumatoid arthritis
2018 Standout
Rheumatoid arthritis
2016 Standout
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
Tocilizumab – A novel therapy for non-organ-specific autoimmune diseases
2012
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
2013
The pro- and anti-inflammatory properties of the cytokine interleukin-6
2011 Standout
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
2015
Trial of Tocilizumab in Giant-Cell Arteritis
2017 Standout
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
2018
Obesity and inflammation: the linking mechanism and the complications
2016 Standout
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
2020 Standout
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
2012
New therapies for inflammatory bowel disease: from the bench to the bedside
2011
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
2013
Interleukin-6 in bone metastasis and cancer progression
2010
IL-6 in Inflammation, Immunity, and Disease
2014 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Tocilizumab: A Review in Rheumatoid Arthritis
2017
GP130 cytokines and bone remodelling in health and disease
2010
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy
2014 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Averting inflammation by targeting the cytokine environment
2010
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
2016
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
2014
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
2020 Standout
Ulcerative colitis
2020 Standout
The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis
2010
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
2017
Tocilizumab for rheumatoid arthritis
2010
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis
2021 StandoutNobel
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
2013
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
2014
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
2010
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
2011
Interleukin‐6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute‐phase reactants
2010
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
2020 Standout
Psoriasis Pathogenesis and Treatment
2019 Standout
Overview of pharmacological activities ofAndrographis paniculataand its major compound andrographolide
2018 Standout
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study
2017
Cytokine Storm
2020 Standout
Therapeutic Targeting of the Interleukin-6 Receptor
2011
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
2011
Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations
2013
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
2016
Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis
2018
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
2017
Chronic Inflammation and Cytokines in the Tumor Microenvironment
2014 Standout
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis
2017
Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums
2013
Design of the Tocilizumab in Giant Cell Arteritis Trial
2013
Works of Daniel Siri being referenced
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
2009